EASL HCV Highlights: Gilead's Next-Gen Data May Reinforce Market Dominance
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck unveils solid head-to-head data for Zepatier versus Sovaldi, but comparator is a regimen barely used anymore. AbbVie provides real-world cure data for its hepatitis C regimens.